Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> Citi Slightly Cuts Sinopharm (01099.HK) TP to HKD22.6; 1Q26 Results Largely In Line
Recommend 4 Positive 4 Negative 2 |
||||
|
||||
|
Citi published a research report stating that Sinopharm (01099.HK) recorded revenue of RMB140.8 billion in 1Q26, down 0.6% YoY and largely in line with the banks expectations. By segment, management indicated that pharmaceutical distribution revenue edged down YoY, while the YoY decline in medical device distribution narrowed, signaling preliminary stabilization in this business. More encouragingly, retail business revenue increased 5% YoY. Citi expects industry consolidation to continue, with Sinopharm likely to gain market share in lower-tier cities through ongoing city-level network expansion. Given the continued weakness in pharmaceutical distribution, Citi lowered its revenue forecasts for 20262028 by 2%, 2% and 3%, respectively, and trimmed net profit forecasts for the same period by 1%, 1% and 1%. The TP was slightly reduced from HKD22.8 to HKD22.6, with the Buy rating maintained. (hc/a) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
